Cipla, one of India's major pharmaceutical companies, reported a significant 55% decline in its consolidated net profit for the fourth quarter ending March, totaling ₹555 crore. The company's total income from operations also saw a 3% decrease, amounting to ₹6,541 crore. For the full fiscal year 2026, Cipla achieved a revenue of ₹28,163 crore, reflecting a modest 2% growth year-on-year, while its annual profit after tax (PAT) dropped 26% to ₹3,879 crore. The Board of Directors has proposed a final dividend of ₹13 per equity share, which has a face value of ₹2. Achin Gupta, the Managing Director and Global CEO of Cipla, emphasized the company's commitment to growth in key markets and the development of flagship brands. He noted that the India business grew by 15% year-on-year and that the company invested ₹509 crore in research and development, representing 7.8% of sales for the quarter. Cipla aims to continue its focus on regulatory resolutions and strengthening its market position.